Journals / Turkish Journal of Gastroenterology / 2011 / Cilt: 22 - Sayı: 5

Ratlarda TNBS ile oluflturulan kolitin probiyotikler ile tedavisi

Treating TNBS-Induced colitis in rats with probiotics

Pages
486–493
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Peifeikang can effectively ameliorate trinitrobenzene sulfonic acid-induced colitis in rats, the underlying mechanism of which may be attributed to the modulatory effects of Peifeikang on the production of tumor necrosis factor-alpha and interleukin-10..

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: We aimed to investigate the therapeutic effects of Peifeikang, a probiotics compound, on colitis in rats induced by trinitrobenzene sulfonic acid and to elucidate its potential mechanism.
📊
Key Findings & Data:Material and Methods: We evaluated the therapeutic effects of Peifeikang by analysis of the disease activity index, colonic mucosa damage index, and histopathological score of the inflamed colons, by measurement of colonic myeloperoxidase activity through spectrophotometric assay, by determination of colonic positivities of tumor necrosis factor-alpha and interleukin-10 via immunochemical staining, and by detection of serum levels of tumor necrosis factor-alpha and interleukin-10 with enzyme-linked immunosorbent assay.
💡
Conclusion & Impact:Conclusions: Peifeikang can effectively ameliorate trinitrobenzene sulfonic acid-induced colitis in rats, the underlying mechanism of which may be attributed to the modulatory effects of Peifeikang on the production of tumor necrosis factor-alpha and interleukin-10..
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: We aimed to investigate the therapeutic effects of Peifeikang, a probiotics compound, on colitis in rats induced by trinitrobenzene sulfonic acid and to elucidate its potential mechanism. Material and Methods: We evaluated the therapeutic effects of Peifeikang by analysis of the disease activity index, colonic mucosa damage index, and histopathological score of the inflamed colons, by measurement of colonic myeloperoxidase activity through spectrophotometric assay, by determination of colonic positivities of tumor necrosis factor-alpha and interleukin-10 via immunochemical staining, and by detection of serum levels of tumor necrosis factor-alpha and interleukin-10 with enzyme-linked immunosorbent assay. Results: Intrarectal administration of trinitrobenzene sulfonic acid caused colonic inflammation similar to human ulcerative colitis with significantly increased disease activity index, colonic mucosa damage index, histopathological score, and colonic myeloperoxidase activities (p<0.05). After treatment with Peifeikang or olsalazine alone, or both, disease activity index, colonic mucosa damage index, histopathological score, and colonic myeloperoxidase activities decreased significantly (p<0.05). The relief of trinitrobenzene sulfonic acid-induced colitis was accompanied by significantly decreased production of tumor necrosis factor-alpha in both serum and intra-colon (p<0.05) and by significantly increased production of interleukin-10 in both serum and intra-colon (p<0.05). Conclusions: Peifeikang can effectively ameliorate trinitrobenzene sulfonic acid-induced colitis in rats, the underlying mechanism of which may be attributed to the modulatory effects of Peifeikang on the production of tumor necrosis factor-alpha and interleukin-10..

Özet

Bu çalışmada ratlarda trinitrobenzen sulfonik asit ile oluşturulan kolitte, probiyotik olan Peifeikang’ın terapötik etkisini araştırmayı ve etkisinin potansiyel mekanizmasını aydınlatmayı amaçladık. Yöntem: Peifeikang’ın terapötik etkinliği, hastalık aktivitesi indeksi, kolon mukozası hasar indeksi ve inflame kolon mukozasında spektrofotometrik yöntemle ölçülen kolonik myeloperoksidaz aktivitesi ile elde edilen histopatolojik skor, immunhistokimyasal incelemede kolonda tümör nekrozis faktörü-alfa (TNF-a) ve interlökin-10 boyanma düzeyi, serum TNF-a ve interlökin-10 düzeylerinin ölçümü (ELISA) ile değerlendirilmiştir. Bulgular: Trinitrobenzen sulfonik asitin intrarektal uygulanmasının insanlardaki ülseratif kolite benzer inflamasyona ve hastalık aktivitesi indeksi, kolon mukozası hasar indeksi, histopatolojik skorlaması ve myeloperoksidaz aktivitesi değerlerinde anlamlı artışa neden olduğu görüldü (p<0.05). Tek başına Peifeikang veya olsalazine uygulamasının ertesinde veya kombine uygulama sonrasında, hastalık aktivitesi indeksi, kolon mukozası hasar indeksi, histopatolojik skorlaması ve kolonik myeloperoksidaz aktivitesi değerlerinde anlamlı azalma gözlendi (p<0.05). Trinitrobenzen sulfonik asit ile indüklenen kolitin iyileşmesine serumda ve kolon dokusunda TNF-a düzeylerinde anlamlı azalma ve interlökin-10 düzeylerinde anlamlı artış eşlik etmekteydi (p<0.05). Sonuç: Peifeikang trinitrobenzen sulfonik asit ile indüklenen koliti anlamlı düzeyde iyileştirebilmektedir ve altta yatan etki mekanizması TNF-a ve interlökin-10 üretimine olan etkisi ile ilişkili olabilir.

🔖

Cite This Article

MENG, W. Y., QING, Z. Y., BING, X., JUN, L. (2011). Ratlarda TNBS ile oluflturulan kolitin probiyotikler ile tedavisi. Turkish Journal of Gastroenterology, Cilt: 22 - Sayı: 5, 486–493. https://ajindex.com/articles/411134

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 1997; 349: 521-4
  2. Targan SR, Hanuaer SB, van Deventer SJH, et al. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor a for Crohn’s disease. N Engl J Med 1997; 337: 1029-35
  3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76
  4. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74
  5. Herfarth H, Bocker U, Janardhanam R, et al. Subtherapeutic corticosteroids potentiate the ability of interleukin10 to prevent chronic inflammation in rats. Gastroenterology 1998; 115: 856-65
  6. Herfarth H, Mohanty S, Rath H, et al. Interleukin-10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996; 39: 836-45
  7. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-33
  8. Ghosh S, van Heel D, Playford RJ. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut 2004; 53: 620-2
  9. Araki Y, Andoh A, Takizawa J, et al. Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int J Mol Med 2004; 13: 577-80
  10. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/SynergyI) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trail. Gut 2005; 54: 5429
  11. Chen N, You P, Liu A, et al. The influence of T regulatory cells on experimental colitis of rats after treatment by probiotics. ZhongHuaXiaoHuaZaZhi 2006; 26: 100-3
  12. Siddiqui A, Ancha HR, Tedesco D, et al. Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosa healing in a rodent model of colitis. Dig Dis Sci 2006; 51: 698-705
  13. Vowinkel T, Kalogeris TJ, Mori M, et a1. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci 2004; 49: 556-64
  14. Wallace JL, Keenan CM, Gale D, et al. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 1992; 102: 18-27
  15. Fedorak RN, Empey LR, MacA